AR080249A1 - Compuestos en calidad de antagonistas de bradiquinina-b1 - Google Patents

Compuestos en calidad de antagonistas de bradiquinina-b1

Info

Publication number
AR080249A1
AR080249A1 ARP110100542A ARP110100542A AR080249A1 AR 080249 A1 AR080249 A1 AR 080249A1 AR P110100542 A ARP110100542 A AR P110100542A AR P110100542 A ARP110100542 A AR P110100542A AR 080249 A1 AR080249 A1 AR 080249A1
Authority
AR
Argentina
Prior art keywords
alkyl
bradiquinina
antagonist
compounds
quality compounds
Prior art date
Application number
ARP110100542A
Other languages
English (en)
Inventor
Juergen Mack
Henning Priepke
Annette Schuler-Metz
Rainer Walter
Norbert Hauel
Angelo Ceci
Henri Doods
Ingo Konetzki
Dieter Wiedenmayer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/052232 external-priority patent/WO2010097372A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR080249A1 publication Critical patent/AR080249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/56—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

Su preparacion, los medicamentos que contienen los compuestos farmacologicamente eficaces, su preparacion y su uso. Reivindicacion 1: Compuestos caracterizados porque tienen la formula general (1) en la cual: R1 es el grupo de formula (2); R2 significa H o -CH3; R3 y R4, junto con el átomo de carbono al que están unidos, un grupo cicloalquileno C3-6, en el que una unidad -CH2 puede estar reemplazada por un átomo de oxígeno; R5 es H o -CH3; R6 es H, F, Cl o metilo; R7 es H, F, Cl, Br, -CN, alquilo C1-4, CF3, CHF2; R8 es H; R9 es F, Cl, Br, alquilo C1-4, -O-alquilo C1-4, -S-alquilo C1-4; R10 es H; R11 es F, Cl, Br, -CN, alquilo C1-4, CF3, CHF2; y X es CH o N; sus enantiomeros, sus diastereoisomeros, sus mezclas y sus sales.
ARP110100542A 2010-02-23 2011-02-22 Compuestos en calidad de antagonistas de bradiquinina-b1 AR080249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/052232 WO2010097372A1 (de) 2009-02-26 2010-02-23 Verbindungen als bradykinin-b1-antagonisten

Publications (1)

Publication Number Publication Date
AR080249A1 true AR080249A1 (es) 2012-03-21

Family

ID=43981434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100542A AR080249A1 (es) 2010-02-23 2011-02-22 Compuestos en calidad de antagonistas de bradiquinina-b1

Country Status (23)

Country Link
EP (1) EP2539323B3 (es)
JP (1) JP5603955B2 (es)
KR (1) KR101843341B1 (es)
CN (2) CN102781916B (es)
AP (1) AP3218A (es)
AR (1) AR080249A1 (es)
AU (1) AU2011219885C1 (es)
CA (1) CA2790952C (es)
CY (1) CY1116182T1 (es)
DK (1) DK2539323T6 (es)
ES (1) ES2531663T7 (es)
HK (1) HK1175171A1 (es)
IL (1) IL220680A (es)
MA (1) MA34008B1 (es)
MX (1) MX2012009224A (es)
NZ (1) NZ601194A (es)
PE (1) PE20121805A1 (es)
PL (1) PL2539323T6 (es)
PT (1) PT2539323E (es)
SG (1) SG183336A1 (es)
SI (1) SI2539323T1 (es)
TW (1) TWI499589B (es)
WO (1) WO2011104203A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
JP5238812B2 (ja) 2007-08-29 2013-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ブラジキニンｂ１アンタゴニスト
EP2539323B3 (de) 2010-02-23 2017-10-04 Boehringer Ingelheim International GmbH Verbindungen als Bradykinin-B1-Antagonisten
US8937073B2 (en) * 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
JP5727010B2 (ja) * 2010-08-20 2015-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブラジキニンｂ１受容体のアンタゴニストとしてのピリダジン誘導体
JP7376582B2 (ja) * 2018-10-22 2023-11-08 イーオーイー オレオ ゲーエムベーハー 成形体への圧縮を目的とした粉末材料用添加剤
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038377A1 (es) * 2002-02-08 2005-01-12 Merck & Co Inc Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
IL166426A0 (en) * 2002-08-29 2006-01-15 Merck & Co Inc N-biarylmethyl aminocycloalkanecarboxamide derivatives
CA2534188A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN1926136A (zh) * 2004-03-02 2007-03-07 默克公司 作为缓激肽拮抗剂的氨基环丙烷羧酰胺衍生物
CN101171005A (zh) 2005-05-11 2008-04-30 尼科梅德有限责任公司 Pde4抑制剂罗氟司特与四氢生物蝶呤衍生物的组合
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
EP2539323B3 (de) 2010-02-23 2017-10-04 Boehringer Ingelheim International GmbH Verbindungen als Bradykinin-B1-Antagonisten
PE20120360A1 (es) 2009-02-26 2012-04-14 Boehringer Ingelheim Int Compuestos en calidad de antagonistas de bradiquinina b1

Also Published As

Publication number Publication date
CN103980258A (zh) 2014-08-13
MA34008B1 (fr) 2013-02-01
CA2790952A1 (en) 2011-09-01
PE20121805A1 (es) 2013-01-23
PL2539323T6 (pl) 2018-05-30
EP2539323A1 (de) 2013-01-02
PT2539323E (pt) 2015-02-16
CN102781916A (zh) 2012-11-14
EP2539323B3 (de) 2017-10-04
AU2011219885B2 (en) 2015-10-15
KR20130025864A (ko) 2013-03-12
IL220680A (en) 2015-08-31
AP2012006330A0 (en) 2012-06-30
CN103980258B (zh) 2016-09-07
ES2531663T7 (es) 2018-02-13
AP3218A (en) 2015-04-30
CY1116182T1 (el) 2017-02-08
NZ601194A (en) 2014-10-31
DK2539323T6 (en) 2018-01-02
JP2013519710A (ja) 2013-05-30
TWI499589B (zh) 2015-09-11
KR101843341B1 (ko) 2018-03-30
TW201141848A (en) 2011-12-01
JP5603955B2 (ja) 2014-10-08
SG183336A1 (en) 2012-09-27
AU2011219885C1 (en) 2017-06-29
SI2539323T1 (sl) 2015-03-31
HK1175171A1 (en) 2013-06-28
DK2539323T3 (da) 2015-02-23
CN102781916B (zh) 2014-06-25
CA2790952C (en) 2017-07-04
MX2012009224A (es) 2012-08-23
AU2011219885A1 (en) 2012-08-02
IL220680A0 (en) 2012-08-30
EP2539323B1 (de) 2014-12-03
PL2539323T3 (pl) 2015-05-29
ES2531663T3 (es) 2015-03-18
WO2011104203A1 (de) 2011-09-01

Similar Documents

Publication Publication Date Title
AR080249A1 (es) Compuestos en calidad de antagonistas de bradiquinina-b1
ES2621140T3 (es) Compuestos ácido acilamino y preparaciones alimenticias que los contienen
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY32490A (es) Inhibidores de beta-secretasa
AR082101A1 (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento
AR073136A1 (es) Compuestos de pirrol
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
RS53710B1 (en) UNITS AS B1 BRADIKININ ANTAGONISTS
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
AR054341A1 (es) Combinaciones sinergicas de compuestos activos fungicidas
AR092288A1 (es) Ligandos del receptor ep1
ECSP11010750A (es) Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
AR085920A1 (es) Derivados benzimidazolicos utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
CO6280480A2 (es) Ciclopentanos sustituidos que tienen actividad prostaglandina
AR072880A1 (es) Derivados nitrogenados de la pancratistatina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee